The infliximab group accumulated higher drug and healthcare costs ( 27,487 vs 10,364 ; adjusted mean difference 16,956 ( 95 % CI 14,647 to 19,162 ) ) , while productivity losses did not differ ( 33,804 vs 29,220 ; 3961 ( 95 % CI -3986 to 11,850 ) ) , resulting in higher societal cost compared to the conventional group ( 61,291 vs 39,584 ; 20,916 ( 95 % CI 12,800 to 28,660 ) ) .